Research analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical technology company’s stock.
Several other brokerages have also recently weighed in on BIOL. Ascendiant Capital Markets decreased their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd.
Check Out Our Latest Research Report on BIOL
BIOLASE Stock Performance
Hedge Funds Weigh In On BIOLASE
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC lifted its stake in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent filing with the Securities & Exchange Commission. 8.79% of the stock is currently owned by hedge funds and other institutional investors.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Articles
- Five stocks we like better than BIOLASE
- How to Calculate Return on Investment (ROI)
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Earnings Per Share Calculator: How to Calculate EPS
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Short Selling: How to Short a Stock
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.